€24.42
2.32% today
Xetra, Feb 28, 05:23 pm CET
ISIN
DE000A3ENQ51
Symbol
1SXP
Index
Sector
Industry

SCHOTT Pharma Stock price

€25.00
+1.54 6.56% 1M
-7.30 22.60% 6M
-0.16 0.64% YTD
-13.40 34.90% 1Y
-6.30 20.13% 3Y
-6.30 20.13% 5Y
-6.30 20.13% 10Y
Xetra, Closing price Thu, Feb 27 2025
-0.12 0.48%
ISIN
DE000A3ENQ51
Symbol
1SXP
Index
Sector
Industry

Key metrics

Market capitalization €3.77b
Enterprise Value €3.75b
P/E (TTM) P/E ratio 28.06
EV/FCF (TTM) EV/FCF 81.55
EV/Sales (TTM) EV/Sales 3.93
P/S ratio (TTM) P/S ratio 3.94
P/B ratio (TTM) P/B ratio 4.54
Dividend yield 0.64%
Last dividend (FY25) €0.16
Revenue (TTM) Revenue €954.68m
EBIT (operating result TTM) EBIT €164.38m
Free Cash Flow (TTM) Free Cash Flow €45.99m
Cash position €16.78m
EPS (TTM) EPS €0.89
P/E forward 25.06
P/S forward 3.69
EV/Sales forward 3.68
Show more

Is SCHOTT Pharma a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,809 stocks worldwide.

SCHOTT Pharma Stock Analysis

Unlock Scores for Free

Analyst Opinions

11 Analysts have issued a SCHOTT Pharma forecast:

4x Buy
36%
4x Hold
36%
3x Sell
27%

Analyst Opinions

11 Analysts have issued a SCHOTT Pharma forecast:

Buy
36%
Hold
36%
Sell
27%

Financial data from SCHOTT Pharma

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
955 955
-
100%
- Direct Costs 639 639
-
67%
315 315
-
33%
- Selling and Administrative Expenses 57 57
-
6%
- Research and Development Expense 25 25
-
3%
233 233
-
24%
- Depreciation and Amortization 69 69
-
7%
EBIT (Operating Income) EBIT 164 164
-
17%
Net Profit 134 134
-
14%

In millions EUR.

Don't miss a Thing! We will send you all news about SCHOTT Pharma directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

SCHOTT Pharma Stock News

AD HOC NEWS
16 days ago
SCHOTT Pharma AG & Co. KGaA / DE000A3ENQ51
AD HOC NEWS
16 days ago
Für den Mainzer Pharmazulieferer Schott Pharma DE000A3ENQ51 hat das neue Geschäftsjahr 2024/25 mit Umsatz- und Ergebniseinbußen begonnen.
AD HOC NEWS
16 days ago
MAINZ - Für den Mainzer Pharmazulieferer Schott Pharma DE000A3ENQ51 hat das neue Geschäftsjahr 2024/25 mit Umsatz- und Ergebniseinbußen begonnen.
More SCHOTT Pharma News

Company Profile

Head office Germany
CEO Andreas Reisse
Employees 4,689
Founded 2022
Website www.schott.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today